Improve diagnosis of psychotic disorder of autoimmune origi

Recruiting

Conditions: autoimmunity
psychosis
10037176

Registration Number: NL-OMON53058

Lead Sponsor: niversiteit Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

- Psychotic disorder, defined as one or more of the following symptoms:
hallucinations, delusions, thought disorders or catatonia (standardized
criteria of the CASH)
- Psychotic disorder, defined as one or more of the following symptoms:
hallucinations, delusions, thought disorders or catatonia (standardized
criteria of the CASH)
- Duration of disease shorter than 5 years
- At least 16 years of age
- Capacity to understand the purpose and details of the study in order to
provide written informed consent. Alternatively, in the case of patients during
a period of mental instability, the informed consent will be asked from family
or a legal representative.

Exclusion Criteria

- Other severe brain disease which can interfere in the neurocognitive tests
- Presence of other immune disorders with active treatment
- Psychosis due to drug abuse

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measure of this study is the prevalence of autoantibodies<br /><br>to specific neuronal surface ion channel/receptor proteins: NMDA-r, AMPA-r,<br /><br>GABAB-r, LGI1 and Caspr-2, in patients with an early onset stable psychotic<br /><br>disorder with or without autoimmune encephalitis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>a) Prediction of the presence of autoantibodies on the basis of clinical<br /><br>symptoms (by comparing clinical cognitive and neurological characteristics of<br /><br>patients with a psychotic disorder with or without an underlying autoimmune<br /><br>antibody).<br /><br>b) Identification of the effector functions of the autoantibodies (in vitro<br /><br>studies). Associate autoantibody effector functions with clinical<br /><br>characteristics.<br /><br>c) Study of the BBB integrity in a descriptive way and correlate these data<br /><br>with the clinical characteristics and the presence of autoantibodies.</p><br>